MASTERINVEST Kapitalanlage GmbH Buys 1,008 Shares of Regeneron Pharmaceuticals, Inc. $REGN

MASTERINVEST Kapitalanlage GmbH increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 46.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 3,176 shares of the biopharmaceutical company’s stock after acquiring an additional 1,008 shares during the quarter. MASTERINVEST Kapitalanlage GmbH’s holdings in Regeneron Pharmaceuticals were worth $1,786,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of REGN. PGGM Investments grew its holdings in Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after acquiring an additional 51,900 shares in the last quarter. Founders Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after purchasing an additional 538 shares in the last quarter. Generate Investment Management Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $6,300,000. Osaic Holdings Inc. lifted its position in shares of Regeneron Pharmaceuticals by 55.2% in the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after purchasing an additional 6,073 shares during the period. Finally, Hudson Value Partners LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $398,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Insider Activity

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 8,431 shares of company stock worth $5,733,521 over the last 90 days. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $796.55 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The business’s fifty day simple moving average is $738.12 and its 200-day simple moving average is $628.80. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The company has a market cap of $83.72 billion, a PE ratio of 19.07, a PEG ratio of 2.16 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the previous year, the business earned $12.46 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $627.00 to $860.00 in a research note on Wednesday. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Cantor Fitzgerald raised their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $791.05.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.